This genomic event results in the fusion of the ERG proto-oncogene with the androgen-driven promoter of the TMPRSS2, setting the transcription of the former under hormonal affection and resulting in its over-expression in cancer cells [5]. The gene discussed is ERG; the disease is cancer.